HDAC9 and cancer: Although targeting crucial enzymes in the acetylation/deacetylation pathway, such as HATs/HDACs, has been shown to recover immune response to exert a cancer therapeutic impact, and certain HDAC inhibitors have even been licensed by the FDA for clinical use, there are still a number of issues to be resolved.